Luis Moltó
- Immunology top 10%
- Immune Cell Function and Interaction 14
- Immunotherapy and Immune Responses 7
- Immune cells in cancer 5
-
- Cancer Immunotherapy and Biomarkers 5
-
- Cancer Research and Treatments 2
-
- Bladder and Urothelial Cancer Treatments 11
-
- Glycosylation and Glycoproteins Research 4
- Cell death mechanisms and regulation 3
- Co-authors
- Ronald M. BukowskiJames H. FinkeCharles S. TannenbaumPatricia RaymanLuís ManzanoJoaquı́n CarballidoMelchor Álvarez‐MonCarlos Olivier
- Cited by
- ImmunologyOncologyCancer Research
- Partner nations
- SpainUnited StatesIndia
In The Last Decade
Luis Moltó
25 papers receiving 488 citations
Peers
Comparison fields: 5 of 69
- Immunology 268
- Oncology 200
- Cancer Research 54
- Hematology 31
- Biotechnology 21
Countries citing papers authored by Luis Moltó
This map shows the geographic impact of Luis Moltó's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Moltó with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Moltó more than expected).
Fields of papers citing papers by Luis Moltó
This network shows the impact of papers produced by Luis Moltó. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Moltó. The network helps show where Luis Moltó may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luis Moltó, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 8 | |
| 2 | 2008 | 30 | |
| 3 | 2008 | 35 | |
| 4 | 2004 | 35 | |
| 5 | Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. | 2003 | 7 |
| 6 | 1999 | 4 | |
| 7 | Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. | 1999 | 112 |
| 8 | Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. | 1999 | 34 |
| 9 | 1997 | 6 | |
| 10 | 1997 | 8 | |
| 11 | 1996 | 17 | |
| 12 | 1995 | 9 | |
| 13 | 1994 | 19 | |
| 14 | 1993 | 11 | |
| 15 | 1993 | 8 | |
| 16 | 1993 | 17 | |
| 17 | 1992 | 11 | |
| 18 | 1992 | 1 | |
| 19 | 1991 | 14 | |
| 20 | 1991 | 10 |
About Luis Moltó
Luis Moltó is a scholar working on Immunology, Surgery, Biotechnology, Oncology and Genetics, having authored 25 papers that have together received 499 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (14 papers), Bladder and Urothelial Cancer Treatments (11 papers), Immunotherapy and Immune Responses (7 papers), Immune cells in cancer (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Glycosylation and Glycoproteins Research (4 papers), Cell death mechanisms and regulation (3 papers) and Cancer Research and Treatments (2 papers). The work is most often cited by research in Immunology (268 citations), Oncology (200 citations), Cancer Research (54 citations), Hematology (31 citations) and Biotechnology (21 citations). Luis Moltó has collaborated with scholars based in Spain, United States and India. Frequent co-authors include Ronald M. Bukowski, James H. Finke, Charles S. Tannenbaum, Patricia Rayman, Luís Manzano, Joaquı́n Carballido, Melchor Álvarez‐Mon, Carlos Olivier, Daisuke Kudo and Vladimir Kolenko. Their work appears in journals such as British Journal of Cancer, Cancer, The Journal of Immunology, European Urology and Anti-Cancer Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.